Great Lakes Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Great Lakes Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,376	Closed	-$231K	–	756
2023 Q1	$231K	Sell	2,376 -30	-1%	-$3.11K	﹤0.01%	746
2022 Q4	$249K	Buy	+2,406	New	+$226K	0.01%	588
2022 Q3	–	Sell	-3,195	Closed	-$265K	–	649
2022 Q2	$265K	Sell	3,195 -2,603	-45%	-$207K	0.01%	597
2022 Q1	$447K	Sell	5,798 -3,564	-38%	-$298K	0.01%	542
2021 Q4	$827K	Sell	9,362 -58,282	-86%	-$4.81M	0.01%	460
2021 Q3	$5.23M	Sell	67,644 -31,483	-32%	-$2.48M	0.08%	259
2021 Q2	$8.27M	Buy	99,127 +13,435	+16%	+$1.07M	0.12%	209
2021 Q1	$6.47M	Buy	85,692 +19,347	+29%	+$1.58M	0.1%	229
2020 Q4	$5.82M	Sell	66,345 -1,268	-2%	-$101K	0.11%	222
2020 Q3	$5.14M	Buy	67,613 +14,519	+27%	+$1.47M	0.11%	211
2020 Q2	$6.55M	Sell	53,094 -36,392	-41%	-$3.62M	0.16%	158
2020 Q1	$7.56M	Buy	+89,486	New	+$7.71M	0.22%	119
2019 Q2	–	Sell	-2,504	Closed	-$222K	–	534
2019 Q1	$222K	Buy	+2,504	New	+$232K	﹤0.01%	543
2018 Q4	–	Sell	-2,489	Closed	-$241K	–	571
2018 Q3	$241K	Buy	+2,489	New	+$248K	0.01%	559

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Great Lakes Advisors's BMRN Position: Q2 2023 in Review

Great Lakes Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 2,376 shares — an estimated $231K sold.

Great Lakes Advisors first reported a position in BMRN in Q3 2018 and held it in 14 quarters. The position peaked at $8.27M in Q2 2021. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Great Lakes Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Great Lakes Advisors sold 2,376 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $231K.
Great Lakes Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 14 quarters.
Great Lakes Advisors's BioMarin Pharmaceuticals position peaked at $8.27M in Q2 2021.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Great Lakes Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.